Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neo-antigen TILs in Advanced Solid Tumors
NCT03658785Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2020
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in solid tumor, sponsored by Tongji Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Apr 2020; status: recruiting.
02
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03658785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658785.